{"0":{"dur":1,"text":"Maryellen Giger:\nGood morning."},"2":{"dur":2,"text":"I am a medical physicist imaging scientist."},"5":{"dur":8,"text":"I work in extracting information from images\nand my -- the mouse -- my collaborator, Yuan"},"13":{"dur":4,"text":"Ji, is a biostatistician working in the field\nof genomics."},"18":{"dur":6,"text":"We\u2019re working with the TCGA Breast Phenotype\nResearch Group on extracting information from"},"24":{"dur":1,"text":"the MR images."},"26":{"dur":6,"text":"Unfortunately, Yuan Ji came down ill today;\nhowever, Yitan Zhu is in the audience, and"},"33":{"dur":3,"text":"we have three posters on this."},"36":{"dur":6,"text":"So this is the Breast Phenotype Research Group."},"42":{"dur":7,"text":"It includes various image analysis and genomic\nfolks, NCI, as well as radiologists from around"},"50":{"dur":2,"text":"the country that have worked with these images."},"53":{"dur":5,"text":"And our purpose is to demonstrate using this\ndata set, the role of quantitative radiomics"},"58":{"dur":5,"text":"in characterizing the molecular subtypes of\nbreast cancer, and associating that with genomic"},"63":{"dur":1,"text":"data."},"65":{"dur":6,"text":"We come from a history of research and computer-aided\ndiagnosis, where we\u2019ve used computer vision"},"71":{"dur":6,"text":"techniques to extract out the information,\nand then based on clinical information, create"},"78":{"dur":6,"text":"the knowledge to aid in diagnosis or prognosis\nof the patient and now using it in data mining."},"85":{"dur":2,"text":"A few definitions."},"87":{"dur":5,"text":"So radiomics is the high throughput conversion\nof images to minable data and radiogenomics,"},"93":{"dur":6,"text":"or imaging genomics, is the association of\nthese features with genomics and other omics"},"99":{"dur":1,"text":"data."},"100":{"dur":4,"text":"So we\u2019re interested in asking questions\nabout the relationships seen in these clinical"},"105":{"dur":5,"text":"medical images that are obtained routinely\nin practice, and their relationship with the"},"110":{"dur":2,"text":"biology of cancer."},"112":{"dur":5,"text":"We want to know which correlate, which complement,\nto potential lead to personalized screening"},"118":{"dur":2,"text":"and personalized treatment."},"120":{"dur":6,"text":"Most of you are in this area, and what we\u2019re\ninterested in, is incorporating this radiomics"},"127":{"dur":5,"text":"part into the association and predictive model\ndevelopment."},"133":{"dur":4,"text":"So this is our computerated diagnostic workstation\n[spelled phonetically], which is now our high"},"137":{"dur":2,"text":"throughput MRI phenotyping system."},"140":{"dur":4,"text":"Once the lesion is identified, the computer\nautomatically segments the lesion and pulls"},"145":{"dur":3,"text":"out the various phenotypes."},"148":{"dur":2,"text":"This is our data set."},"150":{"dur":7,"text":"We work with the breast cancer cases from\nthe TCGA where clinical, histopathology, and"},"158":{"dur":5,"text":"genomic data is downloaded using TCGA assembler,\nand molecular subtyping and risk recurrent"},"163":{"dur":4,"text":"values were obtained from the Perou Lab at\nUNC."},"167":{"dur":6,"text":"In this data set, there were only at the time\n91 cases that had imaging data."},"174":{"dur":2,"text":"More are being collected."},"176":{"dur":2,"text":"This is the distribution of those cases."},"179":{"dur":11,"text":"Many are ER positive, PR positive, HER2 negative,\nand most are not triple negative."},"190":{"dur":6,"text":"Most of them are Luminal A in the cancer molecular\nsubtype."},"196":{"dur":5,"text":"And from these cases, we downloaded the breast\nMRI images and do the computational image"},"202":{"dur":2,"text":"analysis phenotyping."},"205":{"dur":3,"text":"Let me take a few moments to talk about breast\nMRI."},"208":{"dur":4,"text":"Since tumors have the increased blood vessels\nand different microvascular density and vessel"},"213":{"dur":7,"text":"permeability, we can look at the -- we can\nobtain MR images over time after injection"},"220":{"dur":2,"text":"of a gadolinium contrast agent."},"222":{"dur":5,"text":"So here we have a pre-contrast, a post-contrast\nand a subtraction, and you can see the tumor"},"228":{"dur":1,"text":"is highlighted."},"230":{"dur":6,"text":"We do this analysis in 4-D. That is, as we\ninject the contrast, we continue to image,"},"237":{"dur":5,"text":"and we can obtain data in 3-D, so 4-D analysis."},"242":{"dur":5,"text":"Most of the figures I\u2019m showing will be\na slice, but the analysis is done in 4-D."},"247":{"dur":3,"text":"What we\u2019re interested in is looking at this\nuptake."},"250":{"dur":6,"text":"So if it's high, uptake is quick and the washout\nis quick, chances are it\u2019s a cancerous lesion,"},"257":{"dur":2,"text":"whereas other ones might be more persistent\nor plateau."},"260":{"dur":4,"text":"It doesn\u2019t me they\u2019re not cancerous, but\nlikely not."},"264":{"dur":3,"text":"The first step we do is to segment the tumor."},"267":{"dur":4,"text":"Here examples are two cases and then read\nare the computer-segmented lesions [spelled"},"272":{"dur":1,"text":"phonetically]."},"273":{"dur":3,"text":"To better give you an idea of what this is,\nthis is a 3-D breast MRI."},"276":{"dur":4,"text":"This is a clinically-obtained breast image."},"281":{"dur":3,"text":"You can see right here is the tumor."},"284":{"dur":4,"text":"And, so this is -- we indicate that tumor\nto the computer."},"289":{"dur":2,"text":"The computer then does the segmentation."},"291":{"dur":5,"text":"Within that segmented region, we are looking\nat characteristics of the tumor, both around"},"296":{"dur":4,"text":"the margin, as well as distribution of uptake\nwithin the tumor."},"301":{"dur":2,"text":"And we're calling this a virtual biopsy."},"304":{"dur":4,"text":"Note here, we can analyze the entire tumor,\nrelatively real biopsy."},"309":{"dur":5,"text":"We\u2019re doing it non-invasively so we can\nrepeat it over time, and we can spatially"},"314":{"dur":6,"text":"know where we\u2019re looking at as opposed to\na surgical biopsy where you\u2019re not quite"},"320":{"dur":1,"text":"sure where the needle is going in."},"322":{"dur":5,"text":"And so we hope to correlate between the two."},"327":{"dur":4,"text":"Once we have that lesion, we then can extract\nout multiple phenotypes."},"332":{"dur":6,"text":"So, we can look at size, volume, maximum linear\nsize, surface area."},"338":{"dur":4,"text":"We look at the shape of the tumor, the sphericity\nor how irregular the shape is."},"343":{"dur":5,"text":"We look at the sharpness of the margin of\nthe tumor, and other features."},"349":{"dur":6,"text":"And based on the uptake, because this is dynamically\nobtained contrast enhanced MRI, we look at"},"355":{"dur":4,"text":"the enhancement heterogeneity and kinetics\nof the uptake and washout."},"359":{"dur":5,"text":"For example here, this is a slice through\none of the tumors and at each of those voxels,"},"365":{"dur":3,"text":"we can look at the uptake over time."},"368":{"dur":4,"text":"And you see that there\u2019s curves on the right\nvery greatly, and that\u2019s the heterogeneity"},"373":{"dur":2,"text":"of the uptake within the tumor."},"375":{"dur":4,"text":"So what we do is we look at, at one point\nin time, how that differs."},"379":{"dur":4,"text":"And we\u2019re interested in relating the heterogeneity\nthat we\u2019re seeing in the imaging, from the"},"384":{"dur":6,"text":"angiogenesis, to the heterogeneity that you\nare seeing in analysis of the genomics at"},"391":{"dur":3,"text":"different locations within the tumor."},"394":{"dur":5,"text":"So we can look at the texture, and we do various\ncomputer-vision texture analysis methods."},"399":{"dur":4,"text":"We look at the uptake and washout, and we\nlook at the variants of that."},"403":{"dur":7,"text":"And those are given as our various phenotypes\nof our noninvasive virtual biopsy."},"411":{"dur":6,"text":"So in the TCIA breast group, we\u2019re relating\nthese computer extracted phenotypes to various"},"417":{"dur":1,"text":"tasks."},"419":{"dur":5,"text":"For example, for clinical tumor status, here\nwe show the surface area extracted by the"},"424":{"dur":6,"text":"computer relative to stage, and we see that\nit is predictive of breast cancer tumor stage."},"431":{"dur":5,"text":"We can look at it relative to molecular classification\nin cancer subtype."},"437":{"dur":5,"text":"For example, we have shown that on this limited\ndata set, that ER negative breast cancers"},"443":{"dur":5,"text":"tended to have larger size, a more irregular\nshape, and were more heterogeneous in terms"},"448":{"dur":2,"text":"of the contrast enhancements."},"451":{"dur":4,"text":"For triple negative, they tended to have a\nmore irregular shape, and more heterogeneous"},"456":{"dur":2,"text":"in terms of the contrast enhancement."},"458":{"dur":3,"text":"What happened?"},"461":{"dur":1,"text":"Oh."},"463":{"dur":1,"text":"Okay."},"465":{"dur":4,"text":"I\u2019m not sure what happened, but okay."},"469":{"dur":4,"text":"We also compare this to the molecular subtype,\nand here we\u2019re showing that the enhancement"},"474":{"dur":5,"text":"texture of the tumor heterogenic appears to\nbe predictive of molecular subtype."},"480":{"dur":6,"text":"And here at the bottom we show normal like,\nLuminal A, Luminal B, HER2-enriched, and basal-like"},"486":{"dur":1,"text":"breast cancers."},"488":{"dur":4,"text":"And as you go across the graft, it gets, the\nprognosis is worse."},"493":{"dur":2,"text":"And this was a statistical trend."},"496":{"dur":4,"text":"Now, in our analyses, and we realize that\nthe tumor size is very important, so we try"},"501":{"dur":5,"text":"to control for that, and we still see this\nenhancement texture of the tumor heterogeneity"},"506":{"dur":5,"text":"being predicted by the molecular subtype as\nshown here, where the plot on the left are"},"512":{"dur":4,"text":"for very small tumors and the one on the right\nis two centimeters to five centimeters."},"516":{"dur":5,"text":"We\u2019ve also related these to the risk or\nrecurrence for multi-gene assays from Chuck"},"522":{"dur":2,"text":"Crews' lab at UNC."},"524":{"dur":3,"text":"Here\u2019s an example of two cancers."},"528":{"dur":2,"text":"The one on the left is one of a good prognostic\ncase."},"531":{"dur":3,"text":"The one on the right is a poor prognostic\ncase."},"534":{"dur":7,"text":"These were analyzed with the research OncotypeDX,\nMammaPrint, and the PAM50 test, as well as"},"542":{"dur":6,"text":"our radiomics, looking at tumor size, tumor\nshape irregularity, and the heterogeneity"},"548":{"dur":1,"text":"of the uptake."},"550":{"dur":6,"text":"And I know you can\u2019t read this, but I put\nthis up only again to show that we are finding"},"557":{"dur":6,"text":"statistically significant correlation, and\nthe same types of features are being shown"},"564":{"dur":6,"text":"again; tumor size, irregularity and uptake\nheterogeneity."},"570":{"dur":3,"text":"Okay."},"573":{"dur":6,"text":"We can also present this in terms of ROC analysis\nin looking at good prognosis versus poor prognosis"},"580":{"dur":3,"text":"for these various research gene assays."},"583":{"dur":5,"text":"And the black curve here on the upper right\nof the ROC analysis is the performance of"},"589":{"dur":9,"text":"these computer-extracted tumor signatures\nin terms of predicting poor and not-so-poor"},"599":{"dur":2,"text":"prognostics."},"601":{"dur":5,"text":"And then ultimately, we can relate these phenotypes\nto genomic pathways."},"606":{"dur":6,"text":"One thing I want to point out is that while\nwe\u2019re pushing imaging to see as much as"},"613":{"dur":5,"text":"we can, what we can see from just the imaging\nalone, it\u2019s not that we would just use imaging."},"619":{"dur":5,"text":"Ultimately, we want to see if we can merge\nimaging with genomics and other features to"},"624":{"dur":4,"text":"come up with a better prognostic signature."},"628":{"dur":8,"text":"Also, we want to ultimately correlate our\nimaging signatures, our virtual biopsy signatures"},"636":{"dur":8,"text":"with actual biopsies, so that we could non-invasively\nfollow a patient over time during therapy,"},"645":{"dur":5,"text":"and also spatially correlate that information."},"650":{"dur":2,"text":"So moving on to the genomic pathways."},"653":{"dur":8,"text":"Here, the data was extracted from the TCGA\nusing the TCGA assembler software again, and"},"661":{"dur":5,"text":"we used the imaging data from the MRIs."},"666":{"dur":5,"text":"We looked at genetic pathways associated with\nthe radio phenotypes, regression analysis"},"672":{"dur":3,"text":"was done, as was clustering analysis."},"675":{"dur":5,"text":"So in the exploratory cluster analysis of\nthe MR phenotypes, significant associations"},"681":{"dur":4,"text":"were found between these radiomic features\nand the clinical outcomes as shown earlier."},"686":{"dur":7,"text":"And, however, this was done using the typical\ngenomic clustering methods, treating the MR"},"693":{"dur":3,"text":"phenotype as another phenotype."},"696":{"dur":8,"text":"The various associations were show with the\nMR phenotypes and various pathway transcriptional"},"704":{"dur":5,"text":"activities, and I will list the posters where\nthis is shown in more detail at the end of"},"710":{"dur":1,"text":"the talk."},"711":{"dur":7,"text":"Here, red is high positive correlation and\ndark green is -- and light green is the high"},"719":{"dur":6,"text":"negative associations."},"725":{"dur":6,"text":"We also identified significant associations,\nand particularly the size phenotype, very"},"731":{"dur":4,"text":"strong, related to various gene expressions\nof pathways."},"736":{"dur":6,"text":"And this enhancement texture heterogeneity\nphenotypes were related again to the MiRNA"},"742":{"dur":1,"text":"expression."},"743":{"dur":5,"text":"So the same phenotypes, looking at them from\ndifferent ways, keep appearing."},"749":{"dur":5,"text":"So in summary, computational quantitative\nMRI analysis shows promise as a means for"},"755":{"dur":5,"text":"high throughput image based phenotyping and\nappears to predict a breast cancer molecular"},"760":{"dur":1,"text":"subtypes."},"762":{"dur":5,"text":"Radiomics of tumor size and enhancement heterogeneity\nappear as dominant phenotypes in classifying"},"768":{"dur":5,"text":"these subtypes and risk a recurrence, and\nsignificant associations were identified between"},"774":{"dur":7,"text":"the phenotypes and molecular features involved\nin multiple regulation layers."},"781":{"dur":7,"text":"A main limitation is that there are only 91\nbreast MRI cases, even though there\u2019s 1,000"},"788":{"dur":1,"text":"breast cancers in the TCGA."},"790":{"dur":6,"text":"TCIA is collecting additional images, and\nwe\u2019re also organizing, outside of that,"},"796":{"dur":5,"text":"a multi-institutional radio mixed network\nto collect cases."},"801":{"dur":6,"text":"For example, at my institution, we\u2019ve collected\n800 breast cancer cases with MRI, and now"},"807":{"dur":5,"text":"we\u2019re collecting the pathology and, if possible,\nthe genomics on them to validate these promising"},"813":{"dur":2,"text":"features."},"816":{"dur":4,"text":"Identification of radiomics of molecular subtypes\nof breast tumors is expected to allow for"},"820":{"dur":6,"text":"these virtual biopsies to augment actual biopsies,\nand ongoing research involves relating and"},"827":{"dur":5,"text":"merging the MR phenotypes with genomic data\nto development and improve predictive models."},"832":{"dur":3,"text":"I\u2019d like to end with these questions."},"836":{"dur":5,"text":"Is it possible to decide targeted therapy\nbased on imaging and genomics association"},"841":{"dur":1,"text":"results?"},"843":{"dur":4,"text":"Can imaging features inform important genomic\nfeatures?"},"847":{"dur":1,"text":"Not in this work."},"848":{"dur":7,"text":"In prior work that we\u2019ve done, in the association\nof future risk of breast cancer, we\u2019ve used"},"855":{"dur":9,"text":"imaging and other genomic association results\nto direct the analysis as opposed to going"},"864":{"dur":3,"text":"to GWAS to improve the statistics."},"868":{"dur":4,"text":"Can integration of imaging in genomic features\nlead to a higher power in prediction, and"},"873":{"dur":7,"text":"can imaging serve as a virtual biopsy be noninvasive,\ncovering the complete tumor, and being repeatable?"},"880":{"dur":7,"text":"I\u2019d like to thank you and reference a workshop\nof the TCIA here on imaging resources for"},"887":{"dur":1,"text":"the TCGA."},"888":{"dur":5,"text":"That\u2019s today at 4:00 and 5:00 in posters\n91, 79, and 105."},"894":{"dur":3,"text":"Thank you."},"897":{"dur":3,"text":"[applause]"},"900":{"dur":8,"text":"Male Speaker:\nThank you for excellent talk."},"908":{"dur":2,"text":"And just two notes."},"911":{"dur":3,"text":"One, radiogenomics right now is used by two\ngroups."},"914":{"dur":2,"text":"The affect of radiation on genome --"},"917":{"dur":1,"text":"Maryellen Giger:\nYes."},"918":{"dur":4,"text":"Male Speaker:\n-- and genes and also the radiomic and genomic"},"922":{"dur":1,"text":"combination."},"923":{"dur":7,"text":"It needs just somehow clarification when we\nare using one term and we are calling it actually"},"931":{"dur":1,"text":"one term."},"932":{"dur":2,"text":"It\u2019s better to be more precise."},"934":{"dur":3,"text":"I totally agree with your usage."},"937":{"dur":7,"text":"In my opinion, radiogenomic more implies radiomic\nand genomic, but there are other opinion also"},"945":{"dur":1,"text":"out there."},"946":{"dur":6,"text":"And the second one is that radiomic in particular\nis able to capture the heterogeneity in the"},"953":{"dur":9,"text":"tumor, and what we have at the moment, at\nleast, is just one snapshot of the genomic."},"962":{"dur":7,"text":"Many times, when you are going to integrate\nthe heterogeneity captured by radiomic, just"},"970":{"dur":6,"text":"one sample in the genomic sequencing, there\nwill be a mismatch and how you\u2019re going"},"977":{"dur":1,"text":"to handle that."},"978":{"dur":2,"text":"We don\u2019t have that ability at the moment\nat least."},"980":{"dur":1,"text":"Maryellen Giger:\nOkay."},"981":{"dur":2,"text":"Well, first off, I completely agree with you\non both points."},"984":{"dur":5,"text":"One, I actually -- the radiomics, I agree\nwith that term."},"990":{"dur":4,"text":"Radiogenomics, actually I prefer saying imaging\ngenomics because of the confusion, because"},"994":{"dur":5,"text":"there are other folks where radiogenomics\nis looking at more of the changes based on"},"999":{"dur":1,"text":"the radiation."},"1001":{"dur":1,"text":"So I completely agree."},"1002":{"dur":4,"text":"That name is sticking, but I will go back\nto pushing for imaging genomics."},"1007":{"dur":6,"text":"I also agree on your second point, and that\u2019s\nexactly why we want to take the imaging data,"},"1013":{"dur":3,"text":"where we can get complete coverage of the\ntumor."},"1016":{"dur":6,"text":"We realize that the genomics is based on maybe\none or two biopsies only, and that the genomic"},"1023":{"dur":6,"text":"heterogeneity is slightly different to the\nimaging heterogeneity that we\u2019re seeing,"},"1029":{"dur":1,"text":"but we need to relay them."},"1030":{"dur":8,"text":"So I have a slide -- I didn't put it in -- it\u2019s\nmy proposal, which I\u2019m pressing for, is"},"1039":{"dur":5,"text":"that we can do whole mount pathology."},"1044":{"dur":4,"text":"So instead of the small slide when there\u2019s\na mastectomy, we have a slide this big, and"},"1049":{"dur":5,"text":"it\u2019s kind of like a slice through the breast\nwhere you have the parenchyma and the tumor."},"1055":{"dur":6,"text":"And what we want to do is spatially orientate\nit, multi-omics relationships, because at"},"1062":{"dur":5,"text":"that point, yes, we can capture the entire\ntumor with imaging."},"1067":{"dur":1,"text":"Right now you can\u2019t do that."},"1069":{"dur":2,"text":"It\u2019s a partial picture with the genomics."},"1071":{"dur":5,"text":"But with a whole mount comparison and what\nwe will do is then, you could do complete"},"1077":{"dur":4,"text":"genomics through the tumor, and you can them\nspatially relate it to the MRI."},"1082":{"dur":2,"text":"In fact, I almost put that slide in."},"1085":{"dur":4,"text":"I did not ask him to ask these two questions,\nbut those are the perfect two questions I"},"1090":{"dur":1,"text":"would want someone to ask me."},"1092":{"dur":5,"text":"And that will help answer that problem of\n-- because once we understand for the cases"},"1097":{"dur":5,"text":"that we do get the entire breast, not only\ncan we look at the tumor, we can do virtual"},"1103":{"dur":2,"text":"biopsy on the stroma around it."},"1106":{"dur":2,"text":"And that\u2019s very important."},"1108":{"dur":6,"text":"So we\u2019re setting up this whole mount pathology\nlab to precisely do that."},"1114":{"dur":4,"text":"And once we can understand that relationship,\nthen for cases where we don\u2019t get the complete"},"1119":{"dur":4,"text":"tumor, we can hopefully rely on what we\u2019re\nseeing in the images, and then do it repeatedly"},"1124":{"dur":1,"text":"over time during treatment."},"1125":{"dur":5,"text":"Male Speaker:\nI just wanted to add that right now, by the"},"1130":{"dur":7,"text":"facilities, by image-guided biopsies and intervention,\nwe have the ability to have the tissue sample"},"1138":{"dur":4,"text":"from the exact location which we know in the\nimage."},"1142":{"dur":6,"text":"And if you just want to correlate the texture\nor whatever of that special location to the"},"1148":{"dur":7,"text":"genes, it\u2019s possible, and interventional\noncology can really provide a very good platform"},"1155":{"dur":1,"text":"for this endeavor."},"1157":{"dur":1,"text":"Thank you."},"1158":{"dur":1,"text":"Maryellen Giger:\nYes, we've done it with the breast cancer"},"1160":{"dur":2,"text":"and also with the prostate cancer."},"1163":{"dur":1,"text":"So thank you for that."},"1164":{"dur":2,"text":"Male Speaker:\nThank you."},"1166":{"dur":3,"text":"Maryellen Giger:\nSo, if you have images of some of your cases"},"1170":{"dur":4,"text":"and you\u2019d like to collaborate, please let\nme know."},"1174":{"dur":2,"text":"[applause]"},"1176":{"dur":5,"text":"Katherine Hoadley:\nSo thank you to all the speakers from this"},"1182":{"dur":1,"text":"morning\u2019s session."},"1183":{"dur":1,"text":"I do have home request."},"1184":{"dur":4,"text":"If you are a speaker in the afternoon session,\nif you can please come up here, right after"},"1189":{"dur":2,"text":"I finish speaking, we\u2019d like to talk to\nyou for a second."},"1192":{"dur":2,"text":"Also, we will have lunch now on your own."},"1195":{"dur":4,"text":"Posters start at 1:00, and we\u2019ll start back\npromptly at 2:00 with session two."},"1199":{"dur":1,"text":"Thank you, everybody."},"1200":{"dur":0,"text":"[end of transcript]"}}